Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Financial Select Sector SPDR Fund — how do they compare? Vertex Pharmaceuticals Incorporated trades at $529.5 (market cap $132.79B), while Financial Select Sector SPDR Fund trades at $57.85. Which is the better fit depends on your goals.
| VRTX | XLF | |
|---|---|---|
Market Cap | $132.79B | — |
Sector | Health | — |
52-Week High | $529.65 | $58.01 |
52-Week Low | $376.62 | $47.80 |
Enterprise Value | $126.92B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
XLF trades at $57.60, down 0.35% on the day, with a bullish technical signal driven by moving averages and strong momentum indicators. The ETF recently touched an all-time high, supported by robust inflows into financial sector ETFs and strong Q2 earnings from major banks. A dividend of $0.19 is scheduled for June 2026, adding income appeal.
Outlook remains positive given sector strength and institutional interest, though overbought RSI levels suggest near-term consolidation risks. Key opportunities include diversification benefits and yield; risks involve interest rate sensitivity and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
